AU2000274467A1 - Host cell obtained by transferring vhl gene into cancer cell or embryonic stem cell and expressing - Google Patents

Host cell obtained by transferring vhl gene into cancer cell or embryonic stem cell and expressing

Info

Publication number
AU2000274467A1
AU2000274467A1 AU2000274467A AU7446700A AU2000274467A1 AU 2000274467 A1 AU2000274467 A1 AU 2000274467A1 AU 2000274467 A AU2000274467 A AU 2000274467A AU 7446700 A AU7446700 A AU 7446700A AU 2000274467 A1 AU2000274467 A1 AU 2000274467A1
Authority
AU
Australia
Prior art keywords
cell
expressing
transferring
embryonic stem
vhl gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2000274467A
Inventor
Hiroshi Kanno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CellFree Sciences Co Ltd
Original Assignee
Fretek Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fretek Co Ltd filed Critical Fretek Co Ltd
Publication of AU2000274467A1 publication Critical patent/AU2000274467A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/30—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from cancer cells, e.g. reversion of tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2000274467A 2000-09-27 2000-09-27 Host cell obtained by transferring vhl gene into cancer cell or embryonic stem cell and expressing Abandoned AU2000274467A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2000/006668 WO2002026977A1 (en) 2000-09-27 2000-09-27 Host cell obtained by transferring vhl gene into cancer cell or embryonic stem cell and expressing

Publications (1)

Publication Number Publication Date
AU2000274467A1 true AU2000274467A1 (en) 2002-04-08

Family

ID=11736526

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2000274467A Abandoned AU2000274467A1 (en) 2000-09-27 2000-09-27 Host cell obtained by transferring vhl gene into cancer cell or embryonic stem cell and expressing

Country Status (5)

Country Link
US (1) US7601344B2 (en)
JP (1) JP4540294B2 (en)
AU (1) AU2000274467A1 (en)
GB (1) GB2385054B (en)
WO (1) WO2002026977A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520322A (en) * 2002-07-19 2005-04-29 Auckland Uniservices Ltd Tumor treating composition and methods
JPWO2005074988A1 (en) * 2004-02-06 2007-10-11 株式会社ロコモジェン Neuronal differentiation inducer
US20090253618A1 (en) * 2005-07-20 2009-10-08 Hiroshi Kanno Neuronal differentiation-inducing peptide and use thereof
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
US20100291042A1 (en) 2007-05-03 2010-11-18 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
KR101514281B1 (en) * 2014-08-08 2015-06-05 한국생명공학연구원 Pharmaceutical composition for the prevention or treatment of cancer comprising complementary dsRNA to the promoter region of VHL gene

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710035A (en) * 1994-07-05 1998-01-20 Human Genome Sciences, Inc. Human elastase IV
GB9911047D0 (en) * 1999-05-12 1999-07-14 Isis Innovation Assay method and means

Also Published As

Publication number Publication date
US20070116692A1 (en) 2007-05-24
GB2385054B (en) 2005-04-27
US7601344B2 (en) 2009-10-13
GB0309490D0 (en) 2003-06-04
GB2385054A (en) 2003-08-13
JPWO2002026977A1 (en) 2004-04-30
WO2002026977A1 (en) 2002-04-04
JP4540294B2 (en) 2010-09-08

Similar Documents

Publication Publication Date Title
AU2001254885A1 (en) Modified ES cells and ES cell-specific gene
AU2002217904A1 (en) Methods for efficiently minig broad data sets for biological markers
AU2002301347A1 (en) Embryonic stem cells and neural progenitor cells derived therefrom
AU2001250036A1 (en) Microdroplet cell culture technique
AU2001257532A1 (en) Adenoviral vectors for tumor specific gene expression and uses thereof
AU2002221665A1 (en) Garage shaped biogas fermenter for the methanisation of biomasse
AU2002237240A1 (en) Histone deacetylase-related gene and protein
AU2000274467A1 (en) Host cell obtained by transferring vhl gene into cancer cell or embryonic stem cell and expressing
AU2001242625A1 (en) Gene sequence
AU2001270478A1 (en) Gene expression in biological conditions
AU2001264488A1 (en) Gene expression cassette and its use
AU6859500A (en) Plant gene
AU2001247444A1 (en) Erbeta-mediated gene expression
AU2002220262A1 (en) Sdf-1 beta expressing tumor cells as tumor vaccines
AUPQ749100A0 (en) New epilespy gene
AU2001285743A1 (en) Adipose-related gene
AU2001288940A1 (en) Gene and sequence variation associated with cancer
AU3839500A (en) Novel mannose isomerase and dna encoding the enzyme
AU2002217911A1 (en) Basal cell carcinoma cultures, methods related thereto and their use
AU6871900A (en) Tsg-like gene
AU2002953015A0 (en) Modified lacz gene
AU2003275946A1 (en) Gene expression in biological conditions
AU1624601A (en) Human wnt gene
AUPQ980600A0 (en) Tumour suppressor gene
AU4144600A (en) Cyp2a6 gene judgment methods